Current Research in Triple-Negative Breast Cancer
Richard S. Finn, MD, discusses current research in triple-negative breast cancer
Richard S. Finn, MD, associate professor of medicine, Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine at UCLA, discusses current research in triple-negative breast cancer (TNBC).
Clinical Pearls:
- TNBC is an area of unmet need and is defined by the absence of a druggable target
- Researchers have studied Src inhibition and PARP inhibition in this space
- A new PARP inhibitor, BMN 673, looks particularly potent forBRCA-mutated breast cancer
- Patients withBRCA-mutated breast cancer are often triple negative
- There is still a need to better understand the biology of TNBC in order to bring the right drugs to these patients
Therapy Type and Site of Metastases Factor into HR+, HER2+ mBC Treatment
December 20th 2024During a Case-Based Roundtable® event, Ian Krop, MD, and participants discussed considerations affecting first- and second-line treatment of metastatic HER2-positive breast cancer in the first article of a 2-part series.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
Imlunestrant Improves PFS in ESR1-Mutant Advanced Breast Cancer
December 13th 2024The phase 3 EMBER-3 trial showed imlunestrant improved PFS over SOC endocrine therapy in ER-positive, HER2-negative advanced breast cancer with ESR1 mutations, though not significantly in the overall population.
Read More
